S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
Log in
NASDAQ:AVRO

AVROBIO Competitors

$14.00
-0.03 (-0.21 %)
(As of 11/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$13.84
Now: $14.00
$14.33
50-Day Range
$13.72
MA: $15.43
$17.10
52-Week Range
$9.76
Now: $14.00
$29.32
Volume375,022 shs
Average Volume292,154 shs
Market Capitalization$510.31 million
P/E RatioN/A
Dividend YieldN/A
Beta1.63

Competitors

AVROBIO (NASDAQ:AVRO) Vs. EDIT, SRNE, MESO, ATRA, SRRK, and CRTX

Should you be buying AVRO stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to AVROBIO, including Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), Mesoblast (MESO), Atara Biotherapeutics (ATRA), Scholar Rock (SRRK), and Cortexyme (CRTX).

Editas Medicine (NASDAQ:EDIT) and AVROBIO (NASDAQ:AVRO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, institutional ownership, earnings and dividends.

Profitability

This table compares Editas Medicine and AVROBIO's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Editas Medicine-99.62%-26.74%-16.38%
AVROBION/A-51.33%-47.65%

Valuation and Earnings

This table compares Editas Medicine and AVROBIO's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Editas Medicine$20.53 million89.42$-133,750,000.00($2.68)-10.99
AVROBION/AN/A$-72,960,000.00($2.66)-5.26

AVROBIO has lower revenue, but higher earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than AVROBIO, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Editas Medicine has a beta of 2.02, indicating that its share price is 102% more volatile than the S&P 500. Comparatively, AVROBIO has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Editas Medicine and AVROBIO, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Editas Medicine14302.25
AVROBIO02502.71

Editas Medicine presently has a consensus price target of $38.6667, suggesting a potential upside of 31.30%. AVROBIO has a consensus price target of $32.1667, suggesting a potential upside of 129.76%. Given AVROBIO's stronger consensus rating and higher probable upside, analysts plainly believe AVROBIO is more favorable than Editas Medicine.

Institutional & Insider Ownership

87.2% of Editas Medicine shares are held by institutional investors. Comparatively, 81.2% of AVROBIO shares are held by institutional investors. 0.9% of Editas Medicine shares are held by insiders. Comparatively, 4.8% of AVROBIO shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

AVROBIO beats Editas Medicine on 8 of the 13 factors compared between the two stocks.

Sorrento Therapeutics (NASDAQ:SRNE) and AVROBIO (NASDAQ:AVRO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, institutional ownership, earnings and dividends.

Profitability

This table compares Sorrento Therapeutics and AVROBIO's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sorrento Therapeutics-760.19%-490.67%-38.31%
AVROBION/A-51.33%-47.65%

Valuation and Earnings

This table compares Sorrento Therapeutics and AVROBIO's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sorrento Therapeutics$31.43 million57.72$-292,070,000.00($2.12)-3.25
AVROBION/AN/A$-72,960,000.00($2.66)-5.26

AVROBIO has lower revenue, but higher earnings than Sorrento Therapeutics. AVROBIO is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Sorrento Therapeutics has a beta of 2.61, indicating that its share price is 161% more volatile than the S&P 500. Comparatively, AVROBIO has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Sorrento Therapeutics and AVROBIO, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sorrento Therapeutics00203.00
AVROBIO02502.71

Sorrento Therapeutics presently has a consensus price target of $27.00, suggesting a potential upside of 291.30%. AVROBIO has a consensus price target of $32.1667, suggesting a potential upside of 129.76%. Given Sorrento Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Sorrento Therapeutics is more favorable than AVROBIO.

Institutional & Insider Ownership

24.1% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 81.2% of AVROBIO shares are held by institutional investors. 3.4% of Sorrento Therapeutics shares are held by insiders. Comparatively, 4.8% of AVROBIO shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Sorrento Therapeutics beats AVROBIO on 7 of the 13 factors compared between the two stocks.

Mesoblast (NASDAQ:MESO) and AVROBIO (NASDAQ:AVRO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, institutional ownership, earnings and dividends.

Profitability

This table compares Mesoblast and AVROBIO's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mesoblast-242.38%-15.49%-11.36%
AVROBION/A-51.33%-47.65%

Valuation and Earnings

This table compares Mesoblast and AVROBIO's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mesoblast$32.16 million55.74$-77,940,000.00($0.74)-20.65
AVROBION/AN/A$-72,960,000.00($2.66)-5.26

AVROBIO has lower revenue, but higher earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than AVROBIO, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Mesoblast has a beta of 3.87, indicating that its share price is 287% more volatile than the S&P 500. Comparatively, AVROBIO has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Mesoblast and AVROBIO, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mesoblast01402.80
AVROBIO02502.71

Mesoblast presently has a consensus price target of $15.85, suggesting a potential upside of 3.73%. AVROBIO has a consensus price target of $32.1667, suggesting a potential upside of 129.76%. Given AVROBIO's higher probable upside, analysts plainly believe AVROBIO is more favorable than Mesoblast.

Institutional & Insider Ownership

2.5% of Mesoblast shares are held by institutional investors. Comparatively, 81.2% of AVROBIO shares are held by institutional investors. 18.8% of Mesoblast shares are held by insiders. Comparatively, 4.8% of AVROBIO shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Mesoblast beats AVROBIO on 7 of the 13 factors compared between the two stocks.

Atara Biotherapeutics (NASDAQ:ATRA) and AVROBIO (NASDAQ:AVRO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, institutional ownership, earnings and dividends.

Risk and Volatility

Atara Biotherapeutics has a beta of 2.26, indicating that its share price is 126% more volatile than the S&P 500. Comparatively, AVROBIO has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500.

Profitability

This table compares Atara Biotherapeutics and AVROBIO's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atara BiotherapeuticsN/A-94.86%-82.17%
AVROBION/A-51.33%-47.65%

Institutional & Insider Ownership

98.3% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 81.2% of AVROBIO shares are held by institutional investors. 4.3% of Atara Biotherapeutics shares are held by insiders. Comparatively, 4.8% of AVROBIO shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Atara Biotherapeutics and AVROBIO's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atara BiotherapeuticsN/AN/A$-290,980,000.00($5.67)-4.05
AVROBION/AN/A$-72,960,000.00($2.66)-5.26

AVROBIO is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for Atara Biotherapeutics and AVROBIO, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atara Biotherapeutics01802.89
AVROBIO02502.71

Atara Biotherapeutics presently has a consensus price target of $31.50, suggesting a potential upside of 37.02%. AVROBIO has a consensus price target of $32.1667, suggesting a potential upside of 129.76%. Given AVROBIO's higher probable upside, analysts plainly believe AVROBIO is more favorable than Atara Biotherapeutics.

Summary

AVROBIO beats Atara Biotherapeutics on 7 of the 11 factors compared between the two stocks.

Scholar Rock (NASDAQ:SRRK) and AVROBIO (NASDAQ:AVRO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Volatility and Risk

Scholar Rock has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Comparatively, AVROBIO has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500.

Profitability

This table compares Scholar Rock and AVROBIO's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Scholar Rock-301.13%-61.68%-35.74%
AVROBION/A-51.33%-47.65%

Institutional and Insider Ownership

66.3% of Scholar Rock shares are owned by institutional investors. Comparatively, 81.2% of AVROBIO shares are owned by institutional investors. 24.6% of Scholar Rock shares are owned by insiders. Comparatively, 4.8% of AVROBIO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Scholar Rock and AVROBIO's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scholar Rock$20.49 million73.39$-51,000,000.00($1.85)-24.16
AVROBION/AN/A$-72,960,000.00($2.66)-5.26

Scholar Rock has higher revenue and earnings than AVROBIO. Scholar Rock is trading at a lower price-to-earnings ratio than AVROBIO, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Scholar Rock and AVROBIO, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Scholar Rock00303.00
AVROBIO02502.71

Scholar Rock currently has a consensus target price of $46.00, indicating a potential upside of 2.91%. AVROBIO has a consensus target price of $32.1667, indicating a potential upside of 129.76%. Given AVROBIO's higher probable upside, analysts plainly believe AVROBIO is more favorable than Scholar Rock.

Summary

AVROBIO beats Scholar Rock on 7 of the 13 factors compared between the two stocks.

Cortexyme (NASDAQ:CRTX) and AVROBIO (NASDAQ:AVRO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Volatility and Risk

Cortexyme has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Comparatively, AVROBIO has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500.

Profitability

This table compares Cortexyme and AVROBIO's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CortexymeN/A-37.78%-35.24%
AVROBION/A-51.33%-47.65%

Institutional and Insider Ownership

51.6% of Cortexyme shares are owned by institutional investors. Comparatively, 81.2% of AVROBIO shares are owned by institutional investors. 19.8% of Cortexyme shares are owned by insiders. Comparatively, 4.8% of AVROBIO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Cortexyme and AVROBIO's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CortexymeN/AN/A$-36,980,000.00($1.94)-25.06
AVROBION/AN/A$-72,960,000.00($2.66)-5.26

Cortexyme is trading at a lower price-to-earnings ratio than AVROBIO, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Cortexyme and AVROBIO, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cortexyme00403.00
AVROBIO02502.71

Cortexyme currently has a consensus target price of $68.3333, indicating a potential upside of 40.57%. AVROBIO has a consensus target price of $32.1667, indicating a potential upside of 129.76%. Given AVROBIO's higher probable upside, analysts plainly believe AVROBIO is more favorable than Cortexyme.

Summary

Cortexyme beats AVROBIO on 6 of the 11 factors compared between the two stocks.


AVROBIO Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Editas Medicine logo
EDIT
Editas Medicine
1.4$29.45-1.5%$1.84 billion$20.53 million-16.93
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$6.90-1.7%$1.81 billion$31.43 million-4.23Upcoming Earnings
Mesoblast logo
MESO
Mesoblast
1.0$15.28-9.6%$1.79 billion$32.16 million-20.93Earnings Announcement
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.7$22.99-0.8%$1.79 billionN/A-4.98Analyst Report
Scholar Rock logo
SRRK
Scholar Rock
1.1$44.70-4.5%$1.50 billion$20.49 million-20.60
CRTX
Cortexyme
1.4$48.61-4.4%$1.43 billionN/A-20.25
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.5$9.77-2.0%$1.38 billion$102.43 million-11.77
TBIO
Translate Bio
1.4$18.23-0.1%$1.35 billion$7.80 million-10.66
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.5$13.81-2.9%$1.35 billion$250,000.00-10.87
REGENXBIO logo
RGNX
REGENXBIO
1.7$35.65-0.8%$1.33 billion$35.23 million-9.77
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$18.05-3.6%$1.30 billion$356.07 million8.85
BDTX
Black Diamond Therapeutics
1.4$33.43-1.6%$1.20 billionN/A-5.53Analyst Report
Vericel logo
VCEL
Vericel
1.4$24.96-7.2%$1.13 billion$117.85 million-2,496.00Insider Selling
ALEC
Alector
1.3$13.29-0.5%$1.05 billion$21.22 million-5.96
Cellectis logo
CLLS
Cellectis
1.4$22.42-0.6%$952.54 million$22.99 million-11.93
TCRR
TCR2 Therapeutics
1.2$27.75-4.3%$927.46 millionN/A-11.37
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$46.26-1.6%$911.69 millionN/A-37.31
PASG
Passage Bio
1.7$18.70-4.4%$851.50 millionN/A0.00
Compugen logo
CGEN
Compugen
1.4$12.33-1.1%$843.62 million$17.80 million-33.32
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.6$4.76-2.1%$840.45 million$48.83 million-6.26Analyst Report
NantKwest logo
NK
NantKwest
1.5$7.54-0.7%$818.79 million$40,000.00-10.62Upcoming Earnings
Vaxart logo
VXRT
Vaxart
1.3$6.40-2.3%$700.60 million$9.86 million-10.85Insider Selling
Agenus logo
AGEN
Agenus
1.6$3.51-4.0%$667.42 million$150.05 million-3.22
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$16.50-3.2%$636.97 million$42.74 million-15.00
DTIL
Precision BioSciences
1.5$11.51-2.0%$604.05 million$22.24 million-5.73Analyst Report
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.5$4.61-5.2%$599.80 million$1.12 million-4.66Heavy News Reporting
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.9$12.74-1.4%$596.42 million$69.89 million-3.04
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$6.13-1.5%$544.72 millionN/A-9.58Analyst Downgrade
Proteon Therapeutics logo
PRTO
Proteon Therapeutics
0.8$24.42-4.2%$541.61 millionN/A-21.23
OYST
Oyster Point Pharma
1.7$20.74-0.5%$536.50 millionN/A-1.90
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.7$6.54-1.8%$529.24 millionN/A-2.95
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.73-5.8%$527.40 million$13.29 million-9.74High Trading Volume
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.2$10.58-4.3%$475.92 million$2.91 million-3.69Analyst Report
Heavy News Reporting
ORTX
Orchard Therapeutics
1.6$4.79-5.0%$465.90 million$2.51 million-2.62
IPHA
Innate Pharma
1.2$5.18-0.4%$409.12 million$96.12 million-15.24Analyst Report
HARP
Harpoon Therapeutics
1.6$14.59-1.2%$370.29 million$5.78 million-6.85
Cellular Biomedicine Group logo
CBMG
Cellular Biomedicine Group
0.6$18.64-1.1%$362.72 million$340,000.00-6.59Analyst Downgrade
PRVL
Prevail Therapeutics
1.7$10.15-1.8%$347.60 millionN/A-4.28
CABA
Cabaletta Bio
1.6$14.09-2.2%$338.94 millionN/A-10.28
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.3$2.58-2.7%$319.78 million$4.13 million-5.73High Trading Volume
Heavy News Reporting
Surface Oncology logo
SURF
Surface Oncology
1.3$7.75-0.0%$315.25 million$15.36 million-8.81Analyst Upgrade
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.5$8.38-0.4%$313.97 million$104.39 million-5.11Unusual Options Activity
PDL BioPharma logo
PDLI
PDL BioPharma
1.3$2.56-2.3%$292.42 million$54.76 million-1.92
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.4$8.75-3.3%$284.66 millionN/A-3.60Unusual Options Activity
TARA
Protara Therapeutics
2.2$24.42-4.2%$273.80 millionN/A0.00
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
2.0$6.69-1.9%$266.60 million$147.87 million10.79Insider Selling
DBV Technologies logo
DBVT
DBV Technologies
1.4$2.37-1.3%$260.35 million$14.75 million-1.02Unusual Options Activity
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.7$9.31-1.8%$238.64 million$20,000.000.00
Cardiff Oncology logo
TROV
Cardiff Oncology
0.6$21.31-8.2%$234.64 million$250,000.00-7.03
AXLA
Axcella Health
1.8$5.65-5.7%$212.11 millionN/A-2.63Analyst Report
This page was last updated on 11/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.